A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma
ICARuS II (Intraperitoneal Chemotherapy After cytoReductive Surgery): A Multicenter, Randomized Phase II Trial of Normothermic Intraperitoneal Chemotherapy and Intravenous Chemotherapy After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma
Sponsor: Memorial Sloan Kettering Cancer Center
Listed as NCT06057935, this PHASE2 trial focuses on Malignant Mesothelioma and Malignant Peritoneal Mesothelioma and remains actively recruiting participants. Sponsored by Memorial Sloan Kettering Cancer Center, it has been updated 9 times since 2023, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Recruiting PHASE2
-
Aug 2025 — Sep 2025 [monthly]
Recruiting PHASE2
-
Jul 2025 — Aug 2025 [monthly]
Recruiting PHASE2
-
Jun 2025 — Jul 2025 [monthly]
Recruiting PHASE2
-
Nov 2024 — Jun 2025 [monthly]
Recruiting PHASE2
▶ Show 4 earlier versions
-
Sep 2024 — Nov 2024 [monthly]
Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2
-
May 2024 — Jul 2024 [monthly]
Recruiting PHASE2
-
Oct 2023 — May 2024 [monthly]
Recruiting PHASE2
First recorded
Sep 2023
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Memorial Sloan Kettering Cancer Center
For direct contact, visit the study record on ClinicalTrials.gov .